Smith Salley Wealth Management’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Smith Salley Wealth Management’s Portfolio NEXI Stock Details NEXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-400	Closed	-$2.1K	–	248
2023 Q3	$2.1K	Hold	400	–	–	﹤0.01%	229
2023 Q2	$2.82K	Hold	400	–	–	﹤0.01%	226
2023 Q1	$3.8K	Sell	400 -40	-9%	-$420	﹤0.01%	226
2022 Q4	$2.67K	Hold	440	–	–	﹤0.01%	223
2022 Q3	$6K	Hold	440	–	–	﹤0.01%	214
2022 Q2	$18K	Hold	440	–	–	﹤0.01%	226
2022 Q1	$46K	Buy	+440	New	+$32.3K	﹤0.01%	237

Other funds holding NEXI

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Smith Salley Wealth Management's NEXI Position: Q4 2023 in Review

Smith Salley Wealth Management sold out of NexImmune, Inc. Common Stock (NEXI) in Q4 2023, closing a stake of 400 shares — an estimated $2.1K sold.

Smith Salley Wealth Management first reported a position in NEXI in Q1 2022 and held it in 7 quarters. The position peaked at $46K in Q1 2022. 11 funds tracked by Wall St. Rank hold NEXI as of Q4 2023.

Smith Salley Wealth Management reported no remaining NexImmune, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Smith Salley Wealth Management sold 400 NexImmune, Inc. Common Stock shares in Q4 2023, an estimated $2.1K.
Smith Salley Wealth Management first reported a position in NexImmune, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Smith Salley Wealth Management's NexImmune, Inc. Common Stock position peaked at $46K in Q1 2022.
11 funds tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q4 2023.

Based on Smith Salley Wealth Management's 13F filing for Q4 2023, filed 24 Jan 2024.